Close

Explore AI

Explore GPTs

Explore AI News

Explore AI Videos

Explore AI for Jobs

Latest Boehringer Ingelheim AI Videos

Find the latest for Boehringer Ingelheim company videos

Follow
... 14:18
AI Gold Rush in Pharma Marketing: Hype or Game-Changer?

Viseven

1+ months ago 2K views

AI is revolutionizing pharmaceutical marketing by enhancing efficiency and strategic capabilities. While many solutions focus on content automation, they often neglect the critical aspect of strategy, which is essential for compliance in a highly regulated industry. Effective AI-enabled solutions should prioritize creating modular and reusable content that aligns with regulatory requirements, thereby speeding up the marketing review process. The future success of companies in this sector depends on their ability to blend AI capabilities with true strategic planning rather than simply increasing speed of content production.
05:40 - 05:55

Struggles with compliance bottlenecks persist despite AI's promise in speeding up reviews.

Machine Learning Healthcare
... 8:
Dickens: AVGO "Mag 8" Company in "Early Days" of A.I.

Schwab Network

1+ months ago 3K views

Broadcom shows strong fundamentals with solid exposure to key markets, particularly in AI. The company is executing well on product innovation and adapting to shifts in demand. Despite market volatility, expectations lean towards a positive earnings report. Broadcom's integration into AI-centric growth paths, especially with partnerships in hyperscale technology, highlights its potential for growth despite macroeconomic pressures. The discussion addresses concerns over timing with earnings and comparisons to industry peers while emphasizing AI's increasing importance in various tech areas.
Broadcom AI hardware Finance
... 9:4
SOUN CEO on "Great Relationship" with NVDA, A.I. Adoption Tailwinds

Schwab Network

1+ months ago 1K views

Kayvon Mohajer, CEO of Soundhound AI, discusses the company's latest quarterly results showing over 100% revenue growth year-over-year, driven by diversified AI applications across various sectors including automotive, healthcare, and energy. The company anticipates doubling revenue to between $157 million and $177 million for the upcoming year, with plans to achieve adjusted EBITDA profitability. The conversation also highlights Soundhound's unique position within AI, its strong partnerships, particularly with Nvidia, and the projected growth of AI customer service technologies and voice-enabled devices in the market.
02:12 - 02:26

Soundhound's consistent annual revenue growth and future AI adoption projections.

SoundHound AI Speech recognition AI Startups
... 13:50
IDOLpro: Generative AI for Chemistry | Tech talk with Amit Kadan

SandboxAQ

1+ months ago 2K views

IDOLpro combines AI and physics to enhance drug design by generating small molecules tailored for specific protein targets. Traditional methods are time-consuming, as they require evaluating vast chemical libraries. In contrast, IDOLpro uses generative AI to jump directly to relevant chemical spaces, optimizing for properties like synthetic accessibility and binding affinity. The framework employs a diffusion model guided by machine learning and physics-based scoring functions, significantly improving the efficiency of drug discovery. Initial evaluations show IDOLpro outperformed existing methods in generating viable drug candidates with desirable properties.
04:00 - 04:04

Iterative grading in IDOLpro enhances molecular properties like binding affinity.

SandboxAQ Machine Learning Research & Innovations
... 8:33
BIGBEAR AI for STOCK Market PREDICTION (BBAI STOCK Market Advisory) Best Short Squeeze Stocks to Buy

PROSTOCKMARKETS

1+ months ago 1K views

Current trends for Big Bear AI stock (BBAI) indicate a bearish outlook, highlighted by a recent significant decline marked by the development of a head-and-shoulders pattern. The stock has identified a psychological support level around $5 per share, but skepticism persists regarding its stability. Various technical indicators, including moving averages and momentum readings, reveal a downward momentum with minimal signs of recovery. The analysis suggests that many investors may panic, exacerbating the potential for further declines below this crucial threshold, making it unlikely that the stock will bounce back significantly in the near future.
BigBear AI Predictive Analytics Finance
... 8:29
BIGBEAR AI for STOCK Market PREDICTION: BBAI STOCK for Short Term Investment Quantum Computing Stock

PROSTOCKMARKETS

1+ months ago 2K views

Big Bear AI's stock (BBAI) continues to experience significant declines, despite the S&P being in positive territory. Recent trading patterns suggest a bearish trend, indicated by the breakdown of key support levels and moving averages. The speaker critiques ill-informed investment advice prevalent on social media, underscoring the serious financial repercussions for those following such guidance. With a breakdown below crucial price levels, further declines seem likely unless clear support emerges around $5 per share, prompting concerns about panic selling among uninformed investors.
04:47 - 05:05

Discussion on the psychological support level at $5 per share and potential implications.

BigBear AI Quantum Computing Finance
... 8:29
IPA Stock - AI Company to Watch (Update)

Blaze Capital

1+ months ago 10K views

Immuno Precise Antibodies (IPA), listed on NASDAQ as IPA, aims to revolutionize healthcare and drug discovery through its patented Lens AI technology. With over 90% of clinical drug developments failing, IPA addresses this challenge by accelerating drug discovery and integrating artificial intelligence with biological data. Their HFT patterns program introduces unique signature sequences, enabling the harmonization of complex biological data. The potential market for AI in drug discovery is projected to be worth $24.6 billion by 2029. The company is making strides in developing precision-targeted treatments, particularly for cancer, enhancing drug efficacy with fewer side effects.
04:01 - 04:06

In silico antibodies targeting tumor proteins show AI's efficacy in drug development.

Immunoprecise Antibodies Ltd Finance
... 8:29
IPA Stock - AI Company to Watch (Update)

Blaze Capital

1+ months ago 10K views

Immuno Precise Antibodies (IPA), listed on NASDAQ as IPA, aims to revolutionize healthcare and drug discovery through its patented Lens AI technology. With over 90% of clinical drug developments failing, IPA addresses this challenge by accelerating drug discovery and integrating artificial intelligence with biological data. Their HFT patterns program introduces unique signature sequences, enabling the harmonization of complex biological data. The potential market for AI in drug discovery is projected to be worth $24.6 billion by 2029. The company is making strides in developing precision-targeted treatments, particularly for cancer, enhancing drug efficacy with fewer side effects.
04:01 - 04:06

In silico antibodies targeting tumor proteins show AI's efficacy in drug development.

Immunoprecise Antibodies Ltd Finance